目的观察布拉氏酵母菌散治疗大鼠结肠炎的效果。方法40只Wister大鼠随机分为A、B、c、D四组，其中D组为正常对照组。A、B、c三组经TNBS／乙醇灌肠制备大鼠结肠炎模型。A组：应用布拉氏酵母菌散800mg／kg，溶于1ml生理盐水中灌胃给药；B组：应用柳氮磺胺吡啶200mg／kg，溶于1ml生理盐水中灌胃给药；C组：模型对照组，应用生理盐水1ml／d灌胃；D组：正常Wister大鼠常规饲养。用药7d后观察大鼠一般状态，全麻下心脏采血并取大鼠肠道组织，通过酶联免疫吸附法测定血清及肠道组织免疫组化染色中IL-8、IFN-y的表达。结果A组、B组与c组比较DAI评分（1．62±0．730、1．34±0．605、2．93±0．752），血清IL-8（ng／L）、IFN-1（ng／L）浓度（536．32±38．916、400．38±34．146、783．05±49．522；328±23．166、196±25．642、492±44．244）及肠道组织免疫组化染色中IL-8、1FN-y的表达水平均明显下降（P均〈0．05）；A组检测指标明显高于D组（P〈0．01）；A组血清中IL-8、IFN-y浓度及肠道组织中IFN-y的表达水平高于B组（P〈0．05），而肠道组织中A组与B组IL-8表达水平及DAI评分相比均无统计学差异（P=0．314，P=0．139）。结论布拉氏酵母菌散可降低结肠炎大鼠血清及肠道组织中IL-8、IFN-1水平，对大鼠溃疡性结肠炎模型有治疗作用。

Objective To investigate the effects of celecoxib on rats with 2,4,6-trinitrobenzenesulphonic acid(TNBS)-induced colitis in order to understand its underlying mechanisms in treatment of IBD.Methods 30 male Wistar rats were given 2,4,6-trinitrobenzenesulphonic acid-induced colitis and were randomly divided into three groups,SASP(200 mg/kg) treated group(group B) and celecoxib(10 mg/kg) treated group(group C),0.9% sodium chloride group(group D) with 10 each,another 10 rats were severed as normal control(group A).Except the rats in normal control group,all rats were intragastric administrated and were killed 7-day after colitis treatment and assessed with following variables including pathological change with HE staining of colon;the serum level of PGE2 was detected by enzymelinkde immunosorbent assay(ELISA),respectively.And the COX-2 was measured by immunohistochemistry.Results The DAI in group B,C and D increased since TNBS was administered rectally,but in group C,which was significantly higher than that in group B(P0.01),and was similar to that in the group D(P=0.418);the serum level of PGE2 in group A(75.28±7.55) was significantly lower than that in group B,C and D(P0.05).But in group C,which was significantly lower than that in group B and D(P0.01).Conclusion Celecoxib has no obvious therapeutic effect on TNBS induced ulcers colitis.The celecoxib can reduce the inflammation of colon tissues of experimental colitis induced by TNBS,and decrease expression of the serum PGE2,but even have the tendency of severity of the disease symptoms.Therefore,whether celecoxib can be used in the treatment of ulcerative colitis or not remains to be further researched.

目的 观察布拉氏酵母菌散治疗大鼠结肠炎的效果.方法 40只Wister大鼠随机分为A、B、C、D四组,其中D组为正常对照组.A、B、C三组经TNBS/乙醇灌肠制备大鼠结肠炎模型.A组:应用布拉氏酵母菌散800 mg/kg,溶于1 ml生理盐水中灌胃给药;B组:应用柳氮磺胺吡啶200 mg/kg,溶于1 ml生理盐水中灌胃给药;C组:模型对照组,应用生理盐水1 ml/d灌胃;D组:正常Wister大鼠常规饲养.用药7d后观察大鼠一般状态,全麻下心脏采血并取大鼠肠道组织,通过酶联免疫吸附法测定血清及肠道组织免疫组化染色中IL-8、IFN-γ的表达.结果 A组、B组与C组比较DAI评分(1.62±0.730、1.34±0.605、2.93±0.752),血清IL-8 (ng/L)、IFN-γ(ng/L)浓度(536.32±38.916、400.38±34.146、783.05±49.522;328±23.166、196±25.642、492±44.244)及肠道组织免疫组化染色中IL-8、IFN-γ的表达水平均明显下降(P均＜0.05);A组检测指标明显高于D组(P＜0.01);A组血清中IL-8、IFN-γ浓度及肠道组织中IFN-γ的表达水平高于B组(P＜0.05),而肠道组织中A组与B组IL-8表达水平及DAI评分相比均无统计学差异(P=0.314,P=0.139).结论 布拉氏酵母菌散可降低结肠炎大鼠血清及肠道组织中IL-8、IFN-γ水平,对大鼠溃疡性结肠炎模型有治疗作用.

目的:研究阿立哌唑与利培酮治疗精神分裂症的疗效与安全性。方法:采用CCMD-3精神分裂症的诊断标准,223例精神分裂症患者随机分为阿立哌唑组(109例)和利培酮组(114例),治疗6周。治疗前后用阳性症状和阴性症状量表(PANSS)、临床疗效总评量表(CGI)和副反应量表(TESS)、锥体外系副反应量表(ESRS)评定疗效和安全性。结果:经6周治疗,223例患者完成研究。阿立哌唑组治愈率31.8%,有效率83.3%;利培酮组治愈率39.1%,有效率87.5%(P>0.05)。两组治疗前后PANSS总分、阳性症状、阴性症状、一般精神病理症状评分比较有显著差异(P<0.01)。阿立哌唑组阴性症状分治疗6周末下降较利培酮组明显,有显著差异(P<0.05)。治疗4周末、6周末阿立哌唑组反应缺乏分下降,和利培酮组比较有显著差异(P<0.05)。治疗4,6周末TESS评定阿立哌唑不良反应发生率低于利培酮(P<0.05)。阿立哌唑组主要不良反应是锥体外系副反应、失眠、头昏等。结论:阿立哌唑对精神分裂症患者安全有效。